caa a22 4500 445315725 CHVBK 20180317142646.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10552-011-9794-8 doi (NATIONALLICENCE)springer-10.1007/s10552-011-9794-8 Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer [Elektronische Daten] [Mats Lambe, Annette Wigertz, Hans Garmo, Göran Walldius, Ingmar Jungner, Niklas Hammar] Background: Epidemiological evidence indicates that individuals with type 2 diabetes are at an increased risk of cancer. Elevated glucose levels, below the diagnostic threshold for diabetes, have also been suggested to be associated with increased cancer risks. Methods: We investigated possible associations between glucose levels and the risk of breast, endometrial, and ovarian cancer in a cohort of more than 230,000 women, for which information on outcome and potential confounders was obtained by record linkage to population-based registers. Results: Diabetes was associated with an increased risk of postmenopausal breast cancer (HR=1.22, 95% CI 1.04-1.43). An indication of a slightly elevated breast cancer risk was also found in postmenopausal women with impaired glucose metabolism (HR=1.11, 95% CI 0.96-1.28). Diabetes (HR=1.46, 95% CI 1.09-1.96) and impaired glucose metabolism (HR=1.41, 95% CI 1.08-1.85) were associated with an increased risk of endometrial cancer. No associations were found between glucose levels and ovarian cancer risk. Following adjustment for BMI, estimates were attenuated for endometrial cancer, while point estimates for breast and ovarian cancer remained essentially unchanged. Conclusions: Our results indicate that glucose levels below the diagnostic threshold for diabetes modify the risk not only of endometrial cancer but possibly also of postmenopausal breast cancer. Springer Science+Business Media B.V., 2011 Hyperglycemia nationallicence Diabetes nationallicence Breast cancer nationallicence Endometrial cancer nationallicence Ovarian cancer nationallicence Lambe Mats Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, 171 77, Stockholm, Sweden aut Wigertz Annette Regional Oncologic Centre, Uppsala, Sweden aut Garmo Hans Regional Oncologic Centre, Uppsala, Sweden aut Walldius Göran Department of Medicine, Karolinska Institutet, Stockholm, Sweden aut Jungner Ingmar Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet and CALAB Research, Stockholm, Sweden aut Hammar Niklas Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden aut Cancer Causes & Control Springer Netherlands 22/8(2011-08-01), 1163-1171 0957-5243 22:8<1163 2011 22 10552 https://doi.org/10.1007/s10552-011-9794-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-011-9794-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lambe Mats Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, 171 77, Stockholm, Sweden aut NATIONALLICENCE 700 1- Wigertz Annette Regional Oncologic Centre, Uppsala, Sweden aut NATIONALLICENCE 700 1- Garmo Hans Regional Oncologic Centre, Uppsala, Sweden aut NATIONALLICENCE 700 1- Walldius Göran Department of Medicine, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 700 1- Jungner Ingmar Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet and CALAB Research, Stockholm, Sweden aut NATIONALLICENCE 700 1- Hammar Niklas Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/8(2011-08-01), 1163-1171 0957-5243 22:8<1163 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer